Cardiac glycoside and beta-adrenergic blocker facilitate resuscitation from bupivacaine cardiotoxicity.
de Jong
R H
RH
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D002045:Bupivacaine / Q000009:adverse effects* / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use*; D004347:Drug Interactions; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D012151:Resuscitation
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004077:Digoxin; D002045:Bupivacaine